Livez
Livez46About
What does Livez do?
Livez provides a mobile-first platform for autonomous, personalized preventive medicine. It uses AI and scientific protocols to automatically adapt health plans, book appointments, and recommend screenings based on individual data and health authority guidelines. The service is designed for individuals and employers seeking to proactively manage health and prevent illness.
What is Livez's revenue?
StartupHub estimates Livez's annual revenue at $4.0M (range $2.7M to $9.7M, 68% confidence), based on comparable companies in the sector.
Where is Livez headquartered?
Livez is headquartered in Tel Aviv, Israel.
When was Livez founded?
Livez was founded in 2020.
What industry does Livez operate in?
Livez operates in Healthcare, Preventive Medicine, HealthTech, Longevity, Digital Health, Personalized Health.
How many employees does Livez have?
Livez has approximately 21 people on record.
AI-powered platform for healthcare providers to manage patient WhatsApp messages efficiently.
AI-powered platform for personalized weight management and health coaching.
Clinical Trial Discovery by ENSCORE.
An independent research reference providing accessible, accurate, and transparent information on bioactive peptides and peptide science.
Medbytes provides doctors with a personalized platform for high-impact medical research and news in their specialty.
SYLARIS™ offers premium wearable wellness patches and clinical-grade skincare designed for effortless, intentional, and beautifully designed self-care rituals.
Provider-supervised peptide therapy, NAD+ support, and cognitive enhancement for cellular renewal, recovery, and healthy aging.
Purpose-built WordPress plugins for healthcare and the agencies that serve them.
An entrant is a company tagged HealthTech whose domain was first registered in the window, counted from registry records in the StartupHub directory. 6 of them registered in the last 30 days. Registry detection runs two to three weeks behind registration, so recent weeks are a floor.
No comments yet. Be the first to share your take.